1 / 21

Objectives

CUMC IRB Investigator Meeting Special IND/IDE Considerations: Emergency Use of Investigational Product Compassionate Use & Emergency Research July 21, 2005. Objectives . Today’s session will provide information on: Understanding of Regulatory Requirements and Considerations

aine
Download Presentation

Objectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CUMC IRB Investigator MeetingSpecial IND/IDE Considerations:Emergency Use of Investigational ProductCompassionate Use& Emergency ResearchJuly 21, 2005

  2. Objectives • Today’s session will provide information on: • Understanding of Regulatory Requirements and Considerations • Understanding the Options of Treating Patients with Experimental Therapies • How to Prepare an Application to the IRB for Emergency Research • How to Conduct Community Consultation

  3. FDA Regulations • Code of Federal Regulations: • -Title 21, Parts 50.23 • -Title 21 CFR 50.24 • -Title 21 CFR 312 • -Title 21 CFR 812 • Guidance: -Humanitarian Use Device Exemptions -Guidance on IDE Policies and Procedures

  4. Federal Regulations for the Protection of Subjects from Research Risks45 CFR Part 46Subpart A -- Basic ProtectionsSubpart B -- Pregnant Women, Neonates and Fetuses Subpart C -- PrisonersSubpart D -- Children

  5. Emergency Use of an Investigational Drug or Device

  6. Emergency Use of an Investigational Drug or Device-Medical care with investigational product, not research-Only allowed in emergency, life-threatening situations, when: -no alternative standard treatment is available -another physician concurs with the assessment that the situation is life-threatening and no alternative std. tx is available -all efforts should be made to obtain informed consent-Allowed for ONE time use; subsequent use requires Prospective IRB Approval (CAUTION: Trigger for FDA Audit)

  7. Emergency Use of an Investigational Drug or Device-Distinction between life-threatening and site-threatening -Site threatening (i.e., loss of organ) may be allowed-Should always consult with sponsor (i.e., IND/IDE holder) prior to use of the product in a life-threatening situation-Data may not be used for research purposes

  8. Emergency Use of an Investigational Drug or Device-Sponsor or Pharmacy may request approval from the IRB-IRB will not approve, but will provide authorization letter in accordance with 56.104 and 50.23;-IRB authorization letter should be generated within 3 hours upon submission of all necessary information; -patient’s initials; -drug or device name; -patient’s diagnosis/indication for drug or device

  9. Emergency Use of an Investigational Drug or DeviceAfter use of the drug or device:Within 5 days, must submit the following to the IRB (by letter, not in RASCAL):-documentation that the case was a life-threatening situtation;-concurrence of another physician;-whether or not informed consent was obtained; and if not, what efforts were made to obtain consent;-submit protocol and consent form to the IRB for review if there is any expectation of a future use of the drug or device.

  10. Compassionate Use with an Investigational Drug or Device

  11. Compassionate Use of an Investigational Drug or Device-Generally, intent of providing therapy or treatment to a patient that would not be available in standard practice AND the subject does not qualify for a research study;-Generally, does not fit the emergency, life-threatening criteria.

  12. Compassionate Use of an Investigational Drug or Device -Needs prospective IRB approval and therefore needs a submission in RASCAL;-Needs informed consent obtained in accordance with IRB requirements;-Should have a sponsor’s protocol and investigator’s brochure attached;-Should clearly state that the effort is primarily compassionate use and not research and state if time is of the essence.

  13. Compassionate Use of an Investigational DeviceSome flexibilities are offered by FDA guidances on devices:Humanitarian Device Exemption Regulation: Questions and Answers: Final Guidance for Industry (July 12, 2001)http://www.fda.gov/cdrh/ode/guidance/1381.htmlGuidance on IDE Policies and Procedures (January 20, 1998)http://www.fda.gov/cdrh/ode/idepolcy.html

  14. Compassionate Use of an Investigational Device Flexibilities OfferedHumanitarian Device Exemption Regulation: Questions and Answers: Final Guidance for Industry (July 12, 2001)-HUD may be used for compassionate use;-Consult with sponsor/IDE holder;-Physician should ensure patient protection measures are addressed; -If Research, then submit application in RASCAL; -If Medical Care w/o Research, submit a letter to the IRB (consult with IRB first)-Prior FDA approval is required.

  15. Compassionate Use of an Investigational Device Flexibilities OfferedGuidance on IDE Policies and Procedures (January 20, 1998) – Chapter III, Expanded Access to Unapproved Devices:Individual Patient Access to Investigational Devices Intended for Serious Diseases (falls under 812.35 Supplemental Applications):-Consult with sponsor/IDE holder;-Physician should ensure patient protection measures are addressed; -If Research, then submit application in RASCAL; -If Medical Care w/o Research, submit a letter to the IRB (consult with IRB first);-Concurrence from IRB Chair (not approval) is required;-Prior FDA approval is required.

  16. Emergency Research with an Investigational Drug or Device

  17. Belmont Report, 1979 • Articulates 3 Basic Ethical Principles: Respect For Persons – Autonomy of the Individual Beneficence – Risk Minimization Justice – Burdens and Benefits of Research are Equitably Distributed

  18. Emergency Research with an Investigational Drug or DeviceException from informed consent requirements for emergency research (21 CFR 50.24, October 2, 1996):-Regulations require many additional considerations during IRB review-See Handouthttp://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=50.24

  19. Emergency Research with an Investigational Drug or DeviceCommunity Consultation-Required under 21 CFR 50.24-discussions with, and soliciting opinions from the community/ies in which the study will take place and from which the study subjects will be drawn. -may not always be the same; when they are not the same, both communities should be consulted. -an IRB member or representative should attend these discussions so that they have first-hand knowledge of community reaction.

  20. Emergency Research with an Investigational Drug or Device Community Consultation FDA Guidance: http://www.fda.gov/ora/compliance_ref/bimo/err_guide.htm#COMMUNITY

  21. Emergency Research with an Investigational Drug or Device Community ConsultationSamples of community consultation done by Mayo Clinic: http://www.fda.gov/ohrms/dockets/dailys/04/aug04/083004/95s-0158-sup0028-04-Mayo-Clinic-Rochester-NM-vol28.pdf

More Related